Pitt RBL
Pitt RBL
批准号:
10793942
负责人:
William Paul Duprex
金额:
$287.02万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-18 至 2028-07-31
关键词:
AccelerationAchievementAnimalsBacteriaBiologicalBiologyBiotechnologyBioterrorismCitiesClinicalCollaborationsCommunitiesCountryCountyCreativenessDevelopmentDisciplineDiseaseEmergency SituationEmerging Communicable DiseasesEnsureEnvironmentEquipmentEventEvolutionFundingGoalsHealthHealth SciencesHeartHumanIndustrializationInfectionInfectious Diseases ResearchInfrastructureInternationalInterventionInvestmentsKnowledgeLaboratoriesLeadershipMissionModernizationMonkeysMusOutcomePathogenesisPlayProcessRecording of previous eventsRegulationReportingReproducibilityResearchResearch ActivityResearch PersonnelResourcesRoleRunningScientistSecureServicesStrategic PlanningStructureSupport SystemSystemTherapeutic antibodiesTimeToxinTrainingTraining SupportTranslatingUniversitiesVaccine ResearchVaccinesViralVirusVisionWorkarmbiodefensebiosafety level 3 facilitybiosecuritycohortdata integrityemerging pathogenfightingflexibilityfuture pandemichigh standardmedical countermeasuremedical schoolsmeetingsnanobodiesnoveloperationpandemic diseasepandemic preparednesspathogenpre-clinicalpreclinical developmentpreventprogramsprototyperesponsesmall molecule inhibitorsuccesstransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
OVERALL
ABSTRACT:
The Regional Biocontainment Laboratory (RBL) within the Center for Vaccine Research (CVR) at the University
of Pittsburgh is the biosafety level-3 (BSL-3) hub for infection biology. The mission of the RBL is threefold, to
work on pathogen emergence, evolution and host-to-host transmission, to study the pathogenesis of
emerging infectious diseases and to accelerate pre-clinical development of novel interventions and medical
countermeasures for pandemic preparedness and biodefense. Our vision is to be a globally recognized, highly-
collaborative, creative and forward-facing team of infection biologists who are poised to respond to emerging
biological threats both at the national and international level. The entire facility is registered with the Division of
Select Agents and Toxins (DSAT). It brings together infection biologists and clinicians from a variety of disciplines
who require BSL-3 and animal (A)BSL-3 facilities for their wide ranging viral and bacterial research programs.
We propose to establish Operations, Practices and Integrated Services Cores and formally operationalize our
existing structures. These have evolved from the time the RBL was established, and although they have served
their purpose, require modernization to ensure they will remain current and operationally fit-for-purpose. The
Operations Core will have overall management and budgetary responsibility for the RBL. It will administer the
daily, weekly, monthly and yearly BSL-3 activities essential for the support and services arms of the RBL to
function. This will ensure that the BSL-3 laboratories are run and maintained at the highest standards and they
are safe and secure. The Practices Core will support all the basic functions of the RBL enabling scientific
programs to be rigorously managed and ensuring overall data integrity for reproducible outcomes. It will provide
the requisite theoretical and practical trainings to onboard new RBL Investigators and their teams who wish to
work in BSL-3 and ABSL-3 biocontainment. It will provide biosafety and biosecurity support and guarantee the
facility meets all current compliance regulations for Tier 1 select agent registered laboratories. The Integrated
Services Core will deliver a wide range of high quality BSL-3 and ABSL-3 services for internal users and external
collaborators. These will be rigorously overseen by Academic and Service Leads and reviewed annually with the
assistance of an external RBL Director, other BSL-3 experts and an internal Scientific Advisory Group.
Operational support for the RBL in Pittsburgh will ensure we are ready to support any national response to a
range of emerging infectious diseases in the event of another pandemic or bioterrorism attack. Supporting this
cohort of BSL-3 scientists, who can pivot to work on new pathogens in an emergency, is certain to pay dividends.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Operations Core
-
批准号:10793943
-
项目类别:
-
资助金额:$98.46万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Integrated Services Core
-
批准号:10793945
-
项目类别:
-
资助金额:$115.86万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Practices Core
-
批准号:10793944
-
项目类别:
-
资助金额:$72.71万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
-
批准号:10631339
-
项目类别:
-
资助金额:$332.97万
-
财政年份:2022
-
负责人:William Paul Duprex
-
依托单位:
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization
-
批准号:10444442
-
项目类别:
-
资助金额:$76.9万
-
财政年份:2022
-
负责人:William Paul Duprex
-
依托单位:
Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
-
批准号:10394474
-
项目类别:
-
资助金额:$333.0万
-
财政年份:2021
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8664340
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8504483
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:9064740
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8852530
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:9278078
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8307628
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2011
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8461424
-
项目类别:
-
资助金额:$10.78万
-
财政年份:2006
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8709528
-
项目类别:
-
资助金额:$2.92万
-
财政年份:--
-
负责人:William Paul Duprex
-
依托单位:
海外基金